by Sepideh Saadatmand, H
Amarens Geuzinge, Emiel J T Rutgers, Ritse M Mann, Diderick B W de Roy van
Zuidewijn, Harmien M Zonderland, Rob A E M Tollenaar, Marc B I Lobbes, Margreet
G E M Ausems, Martijne van 't Riet, Maartje J Hooning, Ingeborg Mares-Engelberts,
Ernest J T Luiten, Eveline A M Heijnsdijk, Cees Verhoef, Nico Karssemeijer, Jan
C Oosterwijk, Inge-Marie Obdeijn, Harry J de Koning, Madeleine M A
Tilanus-Linthorst, FaMRIsc study group
The Lancet
Oncology: Articles| volume 20 issue 8, p1136-1147, August 01, 2019
MRI screening detected
cancers at an earlier stage than mammography. The lower number of late-stage
cancers identified in incident rounds might reduce the use of adjuvant
chemotherapy and decrease breast cancer-related mortality. However, the
advantages of the MRI screening approach might be at the cost of more
false-positive results, especially at high breast density.
